Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01507545 · ClinicalTrials.gov registry record · Phase 2
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
A Phase 2 study, sponsored by Morphotek.
- Terminated
- Registry status
- Phase 2
- Development phase
- 154
- Enrollment target
NCT01507545 is a Phase 2 study that was terminated before completion, run by Morphotek. The registered enrollment target is 154 participants.
The verdict
NCT01507545, a Phase 2 study, was terminated before completion, sponsored by Morphotek.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 154 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate whether therapy with MORAb-004 is effective and safe in the treatment of metastatic, colorectal cancer.
Interventions
- DRUG Placebo
- OTHER Best supportive care
- DRUG MORAb-004
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2012-03-27 |
| Est. Completion | 2013-10-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01507545
The ClinicalTrials.gov registry entry for NCT01507545 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 154 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Morphotek, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01507545 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01507545 about?
NCT01507545 is a clinical study titled "Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)". The purpose of this study is to evaluate whether therapy with MORAb-004 is effective and safe in the treatment of metastatic, colorectal cancer.
What is the current status of trial NCT01507545?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 154 participants. The study started on 2012-03-27. Estimated completion is 2013-10-20.
What interventions are being tested in trial NCT01507545?
The interventions under investigation include: Placebo (DRUG), Best supportive care (OTHER), MORAb-004 (DRUG).
Who is sponsoring clinical trial NCT01507545?
This trial is sponsored by Morphotek, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.